Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study
Open accessPublished version of a preprint
The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index; 16 of the 40 sources its claims cite were checked for support.
Abstract
Each additional copy of the apolipoprotein E4 (APOE4) allele is associated with a higher risk of Alzheimer’s dementia, while the APOE2 allele is associated with a lower risk of Alzheimer’s dementia, it is not yet known whether APOE2 homozygotes have a particularly low risk. We generated Alzheimer’s dementia odds ratios and other findings in more than 5,000 clinically characterized and neuropathologically characterized Alzheimer’s dementia cases and controls. APOE2/2 was associated with a low Alzheimer’s dementia odds ratios compared to APOE2/3 and 3/3, and an exceptionally low odds ratio compared to APOE4/4, and the impact of APOE2 and APOE4 gene dose was significantly greater in the neuropathologically confirmed group than in more than 24,000 neuropathologically unconfirmed cases and controls. Finding and targeting the factors by which APOE and its variants influence Alzheimer’s disease could have a major impact on the understanding, treatment and prevention of the disease.
Overview
CoChat Summary
TL;DR
In a large clinically and neuropathologically characterized Alzheimer’s dementia case–control study, APOE2 homozygotes had an exceptionally low likelihood of Alzheimer’s dementia, especially compared with APOE4/4. The impact of APOE2 and APOE4 gene dose was greater in neuropathologically confirmed cases and controls than in neuropathologically unconfirmed groups.
Key findings
- In the neuropathologically confirmed group, APOE2/2 had a significantly lower Alzheimer’s dementia OR than APOE2/3 (0.34, 95% CI 0.12–0.95), an extremely low OR versus APOE3/3 (0.13, 95% CI 0.05–0.36), and an exceptionally low OR versus APOE4/4 (0.004, 95% CI 0.001–0.014).
- APOE4/4 versus APOE3/3 was associated with a much higher OR in the neuropathologically confirmed group (31.22, 95% CI 16.59–58.75) than in the neuropathologically unconfirmed group (10.70, 95% CI 9.12–12.56).
- APOE2 allelic dose OR was lower in the neuropathologically confirmed group (0.38, 95% CI 0.30–0.48) than in the unconfirmed group (0.64, 95% CI 0.58–0.72), while APOE4 allelic dose OR was higher in the confirmed group (6.00, 95% CI 5.06–7.12) than in the unconfirmed group (3.43, 95% CI 3.26–3.60).
- In neuropathologically confirmed cases with available onset ages, mean age at Alzheimer’s dementia onset ranged from 69.9 ± 6.1 years in APOE4/4 to 79.3 ± 9.0 years in the combined APOE2/3 and 2/2 group.
Methods
- Primary analysis used the ADGC neuropathologically confirmed autopsy group: 5,007 brain donors, including 4,018 Alzheimer’s dementia cases and 989 cognitively unimpaired controls; post hoc comparisons used 23,857 neuropathologically unconfirmed clinical participants (10,430 cases, 13,426 controls) and a combined group of 28,864 participants (14,448 cases, 14,416 controls).
- Alzheimer’s dementia ORs were computed for each APOE genotype and for APOE2/APOE4 allelic dose using logistic regression under a generalized linear model, with generalized estimating equations for clinical/combined groups to account for family structure; analyses were performed with and without adjustment for age and sex.
- Additional analyses included ROC curves/AUCs for case–control classification, Kaplan–Meier curves for freedom from Alzheimer’s dementia, and linear regression for CERAD neuritic plaque scores and Braak tau tangle stage, including residual Braak effects after adjustment for CERAD score.
Limitations
- The paper states that although the overall study was unusually large, there were relatively few APOE2 homozygotes, limiting statistical power; it also states that it cannot clarify whether the greater APOE effects in confirmed cases/controls are solely due to excluding neuropathologically misclassified cases/controls or also to brain-donation ascertainment bias.
- The paper states that it cannot exclude an impact of differential disease onset, duration, or survival on Alzheimer’s dementia ORs and AD pathology measures, and that findings from non-Hispanic White groups cannot yet be extended to other ethnic and racial groups.
- Evident from the text: this is a case–control/autopsy-based design, not a prospective cohort, so it does not provide absolute lifetime risk by APOE genotype; the paper also notes it does not provide information about preclinical AD, MCI, or primary diagnoses of other neurodegenerative disorders, and that onset-age estimates may be affected by lack of standardized prospective assessments.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
8 Valid · 3 Not valid · 9 Not checked · 56 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“This possibility has remained unaddressed, because case–control studies without neuropathological or biomarker assessments of AD may have underestimated the impact of APOE genotypes on Alzheimer’s dementia ORs due to the confounding effects of APOE genotypes on the percentages of neuropathologically misclassified cases and controls8–10.”
§ Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study > Introduction
What the sources say
- Partly supportedcites [8] Monsell, S. E. et al. Characterizing apolipoprotein E epsilon4 carriers and noncarriers with the clinical diagnosis of mild to moderate Alzheimer dementia and minimal beta-amyloid peptide plaques. JAMA Neurol. 72, 1124–1131 (2015). sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report minimal AD plaques in 37% of clinically diagnosed APOE4 noncarriers versus 13% of carriers, supporting genotype-related differences in potentially misclassified cases. The paper does not assess misclassified controls or estimate how such misclassification affects case–control odds ratios, so the proposed underestimation is not established by this source. (LLM, conf=0.86)
- Could not verifycites [9] Reiman, E. M. et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proc. Natl Acad. Sci. USA 106, 6820–6825 (2009). sourceExperimental — accuracy not yet measured
The Abstract reports an association between APOE ε4 gene dose and Alzheimer’s disease risk, and the Discussion reports an association with fibrillar amyloid-β burden. Neither addresses whether case–control studies lacking neuropathological or biomarker assessments underestimated dementia odds ratios because of genotype-related misclassification. Searches for misclassified cases and controls and for underestimated case–control odds ratios found no passage addressing that claim. (LLM, conf=0.73)
- Disputedcites [10] Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313, 1924–1938 (2015). sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The study supports known effects of APOE genotypes on standard measures of neuritic Aβ plaque and tau tangle severity13”
§ Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study > Discussion
What the sources say
- Supportedcites [13] Serrano-Pozo, A., Qian, J., Monsell, S. E., Betensky, R. A. & Hyman, B. T. APOEepsilon2 is associated with milder clinical and pathological Alzheimer disease. Ann. Neurol. 77, 917–929 (2015). source
The Results report APOE genotype associations with CERAD neuritic-plaque scores and Braak neurofibrillary-tangle stages. The Abstract Results specify that ε2 is associated with lower Braak stages and possibly fewer plaques, while ε4 is associated with more plaques but has no independent effect on Braak stage. Section labels are available in our copy, but page numbers are not. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Evidence from a person without APOE function due to homozygosity for an ablative APOE frameshift mutation24 and the availability of dyslipidemia treatments support the potential tolerability of this approach.”
§ Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study > Discussion
What the sources say
- Supportedcites [24] Mak, A. C. et al. Effects of the absence of apolipoprotein E on lipoproteins, neurocognitive function, and retinal function. JAMA Neurol. 71, 1228–1236 (2014). source
The Results (Exome Sequencing Results) identify a homozygous APOE frameshift deletion, and the Conclusions report that the resulting absence of apoE did not affect the patient’s neurocognitive or retinal function. The Discussion describes available approaches to treating dyslipidemia, while noting that conventional treatments had been relatively ineffective for this patient. The claim presents potential tolerability as the citing authors’ inference from that evidence. (LLM, conf=0.90)
hedgedstates a possible causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“APOE2 homozygotes were distinguished from the APOE2/3 group by a significantly lower Braak stage (2.26 ± 1.63 versus 3.16 ± 1.69, P < 0.05), before and after adjustment for age and sex.”
§ Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study > Results > Neuritic plaque and neurofibrillary tangle severity
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“such that the protective effect was more than three times greater in the APOE2/2 group than in the APOE2/3 group.”
§ Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study > Results > Neuritic plaque and neurofibrillary tangle severity
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
41 more claims
Create a free account to see all 76 claims and every source verdict.
- It may state two separate claims as one. 19
- Probably not a substantial claim. 18
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous human and animal studies have already established the baseline consequences of APOE3 and APOE4 in the absence of amyloid pathology. 60 , 61 , 62 , 63”
From Apolipoprotein ε4 exacerbates white matter impairment in a mouse model of Aβ amyloidosis by decreasing actively myelinating oligodendrocytes (2025) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, APOE3 is defined as risk-neutral while APOE2 represents the strongest genetic protective factor (Corder et al., 1994; Farrer et al., 1997; Reiman et al., 2020).”
From APOE genotype-dependent differences in human astrocytic energy metabolism (2025) · cites this paper as Reiman et al., 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast to the most common isoform ApoE3, present in 78% of the population, ApoE4 increases the risk of developing AD by three to twelve times depending on whether the ε4 allele is present in heterozygosis or homozygosis [3].”
From ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, the effect size of the APOE genotype on AD risk is now known to depend on a number of variables, including demographics such as race and ethnicity, age and sex, and whether the AD diagnosis is made on clinical or neuropathological8 grounds, or confirmed with biomarkers9.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [8]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study > Discussion
“we did not include persons with the APOE3/4 genotype in our assessment of APOE2 and APOE4 allelic doses.”
§ Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study > Methods > Statistical analysis
“for the assessment of APOE4 allelic dose, we coded APOE3/3, APOE3/4, and APOE4/4 as 0, 1, 2, respectively, in the APOE2 non-carriers.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study > Abstract
“more than 24,000 neuropathologically unconfirmed cases and controls”
§ Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study > Results > Neuropathologically confirmed and unconfirmed groups
“The 23,857 participants in the clinically classified but neuropathologically unconfirmed cohort”
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Self-citationAlzheimer Disease Genetics Consortium (ADGC), Kunkle, B. W., The European Alzheimer’s Disease Initiative (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE), Genetic and Environmental Risk in AD/Defining Genetic, P. A. E. R. F. A. D. C. (., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0358-2 · Cited by 2,946
Self-citationProtective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920
Self-citationNaj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901
Self-citationPrevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Self-citationHYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Self-citationApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220
Self-citationApolipoprotein E: from cardiovascular disease to neurodegenerative disorders
Mahley, R. W. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1427-y · Cited by 837
Reiman, E. M., Chen, K., Liu, X., Bandy, D., Yu, M., Lee, W., Ayutyanont, N., Keppler, J., Reeder, S. A., Langbaum, J. B. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900345106 · Cited by 785
Self-citation
Cited by
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
APOE and Alzheimer’s disease: Advances in genetics, pathophysiology, and therapeutic approaches
Serrano-Pozo, A., Das, S., & Hyman, B. T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30412-9 · Cited by 1,037
Self-citationThe probabilistic model of Alzheimer disease: the amyloid hypothesis revised
Frisoni, G. B., Altomare, D., Thal, D. R., Ribaldi, F., van der Kant, R., Ossenkoppele, R., Blennow, K., Cummings, J., van Duijn, C., Nilsson, P. M., et al. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00533-w · Cited by 513
Yin, F. (2023) · The FEBS Journal · doi:10.1111/febs.16344 · Cited by 441
Sadick, J. S., O’Dea, M. R., Hasel, P., Dykstra, T., Faustin, A., & Liddelow, S. A. (2022) · Neuron · doi:10.1016/j.neuron.2022.03.008 · Cited by 415
Metadata
- Authors
- Reiman, E. M., Arboleda-Velasquez, J. F., Quiroz, Y. T., Huentelman, M. J., Beach, T. G., Caselli, R. J., Chen, Y., Su, Y., Myers, A. J., Hardy, J., Paul Vonsattel, J., Younkin, S. G., Bennett, D. A., De Jager, P. L., Larson, E. B., Crane, P. K., Keene, C. D., Kamboh, M. I., Kofler, J. K., Duque, L., Gilbert, J. R., Gwirtsman, H. E., Buxbaum, J. D., Dickson, D. W., Frosch, M. P., Ghetti, B. F., Lunetta, K. L., Wang, L.-S., Hyman, B. T., Kukull, W. A., Foroud, T., Haines, J. L., Mayeux, R. P., Pericak-Vance, M. A., Schneider, J. A., Trojanowski, J. Q., Farrer, L. A., Schellenberg, G. D., Beecham, G. W., Montine, T. J., Jun, G. R., The Alzheimer’s Disease Genetics Consortium, Abner, E., Adams, P. M., Albert, M. S., Albin, R. L., Apostolova, L. G., Arnold, S. E., Asthana, S., Atwood, C. S., Baldwin, C. T., Barber, R. C., Barnes, L. L., Barral, S., Becker, J. T., Beekly, D., Bigio, E. H., Bird, T. D., Blacker, D., Boeve, B. F., Bowen, J. D., Boxer, A., Burke, J. R., Burns, J. M., Cairns, N. J., Cantwell, L. B., Cao, C., Carlson, C. S., Carlsson, C. M., Carney, R. M., Carrasquillo, M. M., Chui, H. C., Cribbs, D. H., Crocco, E. A., Cruchaga, C., DeCarli, C., Dick, M., Doody, R. S., Duara, R., Ertekin-Taner, N., Evans, D. A., Faber, K. M., Fairchild, T. J., Fallon, K. B., Fardo, D. W., Farlow, M. R., Ferris, S., Galasko, D. R., Gearing, M., Geschwind, D. H., Ghisays, V., Goate, A. M., Graff-Radford, N. R., Green, R. C., Growdon, J. H., Hakonarson, H., Hamilton, R. L., Hamilton-Nelson, K. L., Harrell, L. E., Honig, L. S., Huebinger, R. M., Hulette, C. M., Jarvik, G. P., Jin, L.-W., Karydas, A., Katz, M. J., Kauwe, J. S. K., Kaye, J. A., Kim, R., Kowall, N. W., Kramer, J. H., Kunkle, B. W., Kuzma, A. P., LaFerla, F. M., Lah, J. J., Leung, Y. Y., Leverenz, J. B., Levey, A. I., Li, G., Lieberman, A. P., Lipton, R. B., Lopez, O. L., Lyketsos, C. G., Malamon, J., Marson, D. C., Martin, E. R., Martiniuk, F., Mash, D. C., Masliah, E., McCormick, W. C., McCurry, S. M., McDavid, A. N., McDonough, S., McKee, A. C., Mesulam, M., Miller, B. L., Miller, C. A., Miller, J. W., Morris, J. C., Mukherjee, S., Naj, A. C., O’Bryant, S., Olichney, J. M., Parisi, J. E., Paulson, H. L., Peskind, E., Petersen, R. C., Pierce, A., Poon, W. W., Potter, H., Qu, L., Quinn, J. F., Raj, A., Raskind, M., Reisberg, B., Reisch, J. S., Reitz, C., Ringman, J. M., Roberson, E. D., Rogaeva, E., Rosen, H. J., Rosenberg, R. N., Royall, D. R., Sager, M. A., Sano, M., Saykin, A. J., Schneider, L. S., Seeley, W. W., Smith, A. G., Sonnen, J. A., Spina, S., George-Hyslop, P. S., Stern, R. A., Swerdlow, R. H., Tanzi, R. E., Troncoso, J. C., Tsuang, D. W., Valladares, O., Van Deerlin, V. M., Van Eldik, L. J., Vardarajan, B. N., Vinters, H. V., Weintraub, S., Welsh-Bohmer, K. A., Wilhelmsen, K. C., Williamson, J., Wingo, T. S., Woltjer, R. L., Wright, C. B., Wu, C.-K., Yu, C.-E., Yu, L., & Zhao, Y.
- Affiliations
- Translational Genomics Research Institute (US)
- Harvard University (US)
- Banner Alzheimer’s Institute (US)
- Mayo Clinic in Arizona (US)
- University of Miami (US)
- UCL Queen Square Institute of Neurology (GB)
- Mayo Clinic in Florida (US)
- Rush University Medical Center (US)
- Kaiser Permanente Washington Health Research Institute (US)
- University of Washington (US)
- University of Pittsburgh (US)
- Vanderbilt University (US)
- Icahn School of Medicine at Mount Sinai (US)
- Mayo Clinic (US)
- Massachusetts General Hospital (US)
- Indiana University Indianapolis (US)
- Boston University (US)
- University of Pennsylvania (US)
- Case Western Reserve University (US)
- Columbia University Irving Medical Center (US)
- Stanford Medicine (US)
- University of Kentucky (US)
- The University of Texas Southwestern Medical Center (US)
- Johns Hopkins University (US)
- University of Michigan (US)
- Duke University (US)
- University of Wisconsin–Madison (US)
- University of North Texas Health Science Center (US)
- Northwestern University (US)
- Massachusetts Eye and Ear Infirmary (US)
- Swedish Medical Center (US)
- University of California, San Francisco (US)
- University of Kansas (US)
- Washington University in St. Louis (US)
- University of South Florida (US)
- Fred Hutch Cancer Center (US)
- University of Southern California (US)
- University of California, Irvine (US)
- University of California, Davis (US)
- Baylor College of Medicine (US)
- Mount Sinai Medical Center (US)
- University of Alabama at Birmingham (US)
- New York University (US)
- University of California San Diego (US)
- Emory University (US)
- University of California, Los Angeles (US)
- Brigham and Women's Hospital (US)
- Children's Hospital of Philadelphia (US)
- University of California Davis Medical Center (US)
- Albert Einstein College of Medicine (US)
- Brigham Young University (US)
- Oregon Health & Science University (US)
- Cleveland Clinic (US)
- Pfizer (United States) (US)
- University of Colorado Anschutz (US)
- University of Toronto (CA)
- The University of Texas at San Antonio Health Science Center (US)
- Indiana University Hospital (US)
- University of North Carolina at Chapel Hill (US)
- Texas Tech University (US)
- Corresponding author
- Reiman, Eric M.
- ORCID
- Reiman, Eric M.
- Arboleda-Velasquez, Joseph F.
- Quiroz, Yakeel T.
- Huentelman, Matthew J.
- Beach, Thomas G.
- Caselli, Richard J.
- Chen, Yinghua
- Su, Yi
- Myers, Amanda J.
- Hardy, John
- Bennett, David A.
- Larson, Eric B.
- Crane, Paul K.
- Keene, C. Dirk
- Kamboh, M. Ilyas
- Kofler, Julia K.
- Gilbert, John R.
- Buxbaum, Joseph D.
- Dickson, Dennis W.
- Frosch, Matthew P.
- Ghetti, Bernardino F.
- Lunetta, Kathryn L.
- Hyman, Bradley T.
- Kukull, Walter A.
- Foroud, Tatiana
- Haines, Jonathan L.
- Mayeux, Richard P.
- Pericak-Vance, Margaret A.
- Schneider, Julie A.
- Trojanowski, John Q.
- Farrer, Lindsay A.
- Schellenberg, Gerard D.
- Beecham, Gary W.
- Montine, Thomas J.
- Jun, Gyungah R.
- Abner, Erin
- Adams, Perrie M.
- Albert, Marilyn S.
- Albin, Roger L.
- Apostolova, Liana G.
- Arnold, Steven E.
- Asthana, Sanjay
- Atwood, Craig S.
- Barber, Robert C.
- Barnes, Lisa L.
- Becker, James T.
- Bigio, Eileen H.
- Bird, Thomas D.
- Blacker, Deborah
- Boeve, Bradley F.
- Bowen, James D.
- Boxer, Adam
- Burke, James R.
- Burns, Jeffrey M.
- Cairns, Nigel J.
- Cao, Chuanhai
- Carlsson, Cynthia M.
- Carrasquillo, Minerva M.
- Chui, Helena C.
- Cribbs, David H.
- Crocco, Elizabeth A.
- Cruchaga, Carlos
- DeCarli, Charles
- Duara, Ranjan
- Evans, Denis A.
- Faber, Kelley M.
- Fardo, David W.
- Farlow, Martin R.
- Ferris, Steven
- Galasko, Douglas R.
- Gearing, Marla
- Geschwind, Daniel H.
- Ghisays, Valentina
- Goate, Alison M.
- Green, Robert C.
- Hakonarson, Hakon
- Hamilton, Ronald L.
- Honig, Lawrence S.
- Huebinger, Ryan M.
- Jarvik, Gail P.
- Katz, Mindy J.
- Kaye, Jeffrey A.
- Kowall, Neil W.
- Kramer, Joel H.
- Kunkle, Brian W.
- LaFerla, Frank M.
- Lah, James J.
- Leverenz, James B.
- Levey, Allan I.
- Li, Ge
- Lieberman, Andrew P.
- Lipton, Richard B.
- Lyketsos, Constantine G.
- Malamon, John
- Marson, Daniel C.
- Martin, Eden R.
- Martiniuk, Frank
- Mash, Deborah C.
- Masliah, Eliezer
- McCurry, Susan M.
- McDavid, Andrew N.
- McKee, Ann C.
- Mesulam, Marsel
- Miller, Bruce L.
- Morris, John C.
- Mukherjee, Shubhabrata
- Naj, Adam C.
- O’Bryant, Sid
- Olichney, John M.
- Paulson, Henry L.
- Peskind, Elaine
- Petersen, Ronald C.
- Poon, Wayne W.
- Potter, Huntington
- Qu, Liming
- Quinn, Joseph F.
- Raskind, Murray
- Reisberg, Barry
- Ringman, John M.
- Roberson, Erik D.
- Rogaeva, Ekaterina
- Sano, Mary
- Saykin, Andrew J.
- Schneider, Lon S.
- Seeley, William W.
- Smith, Amanda G.
- Sonnen, Joshua A.
- Spina, Salvatore
- Stern, Robert A.
- Swerdlow, Russell H.
- Tanzi, Rudolph E.
- Troncoso, Juan C.
- Tsuang, Debby W.
- Valladares, Otto
- Vardarajan, Badri N.
- Vinters, Harry V.
- Welsh-Bohmer, Kathleen A.
- Wilhelmsen, Kirk C.
- Wingo, Thomas S.
- Woltjer, Randall L.
- Yu, Chang-En
- Yu, Lei
- Zhao, Yi
- Venue
- Nature Communications
- Published
- 2020-02-03
- Volume
- 11
- Issue
- 1
- Pages
- 667-667
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC6997393
- OpenAlex
- W3003860558
- Cited by
- 473
- References
- 36
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 92 · 2023: 69 · 2022: 74 · 2021: 64 · 2020: 44
- FWCI
- 37.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UA Campus Repository (The University of Arizona) (acceptedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute on Aging (RF1AG057519, P30-AG10161, R01AG15819, R01AG17917)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
- Keywords
- Alzheimer's disease, APOE ε4, apolipoprotein E, gene dosage, dementia risk, neuropathology
- MeSH terms
- Neuropathology, Aged, Aged, 80 and over, Alleles, Alzheimer Disease, Brain, Female, Genotype, Homozygote, Humans, Male, Middle Aged, Probability, Genetic Predisposition to Disease, Apolipoprotein E3, Apolipoprotein E4, Apolipoprotein E2, Genetic Association Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. https://app.cochat.ai/papers/10.1038/s41467-019-14279-8
- The paper
- Reiman, E. M., Arboleda-Velasquez, J. F., Quiroz, Y. T., Huentelman, M. J., Beach, T. G., Caselli, R. J., Chen, Y., Su, Y., Myers, A. J., Hardy, J., Paul Vonsattel, J., Younkin, S. G., Bennett, D. A., De Jager, P. L., Larson, E. B., Crane, P. K., Keene, C. D., Kamboh, M. I., Kofler, J. K., . . . Zhao, Y. (2020). Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nature Communications. https://doi.org/10.1038/s41467-019-14279-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.